Format

Send to

Choose Destination
Cancer Cell. 2017 Sep 11;32(3):377-391.e9. doi: 10.1016/j.ccell.2017.08.004.

Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.

Author information

1
Gene Therapy and Vaccines Program, University of Pennsylvania (U of PA), Philadelphia, PA 19104, USA; The Wistar Institute, Philadelphia, PA 19104, USA.
2
The Wistar Institute, Philadelphia, PA 19104, USA.
3
Lewis-Sigler Institute for Integrative Genomics & Department of Chemistry, Princeton University, Princeton, NJ 08540, USA.
4
Biology Program, Temple University, Philadelphia, PA 19122, USA.
5
Department of Pathology and Laboratory Medicine, U of PA, Philadelphia, PA 19104, USA.
6
Department of Surgery, Hospital of U of PA, Philadelphia, PA 19104, USA.
7
Department of Medicine, U of PA, Philadelphia, PA 19104, USA.
8
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
9
The Wistar Institute, Philadelphia, PA 19104, USA. Electronic address: ertl@wistar.org.

Abstract

How tumor-infiltrating T lymphocytes (TILs) adapt to the metabolic constrains within the tumor microenvironment (TME) and to what degree this affects their ability to combat tumor progression remain poorly understood. Using mouse melanoma models, we report that CD8+ TILs enhance peroxisome proliferator-activated receptor (PPAR)-α signaling and catabolism of fatty acids (FAs) when simultaneously subjected to hypoglycemia and hypoxia. This metabolic switch partially preserves CD8+ TILs' effector functions, although co-inhibitor expression increases during tumor progression regardless of CD8+ TILs' antigen specificity. Further promoting FA catabolism improves the CD8+ TILs' ability to slow tumor progression. PD-1 blockade delays tumor growth without changing TIL metabolism or functions. It synergizes with metabolic reprogramming of T cells to achieve superior antitumor efficacy and even complete cures.

KEYWORDS:

CD8(+) T cells; HIF-1α; TILs; co-inhibitors; fatty acid catabolism; fenofibrate; hypoglycemia; hypoxia; melanoma; tumor microenvironment

PMID:
28898698
PMCID:
PMC5751418
DOI:
10.1016/j.ccell.2017.08.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center